Suratadenoturev
- Generic Name
- Suratadenoturev
- Drug Type
- Biotech
- CAS Number
- 1268642-13-2
- Unique Ingredient Identifier
- FV0JG1SX76
- Background
Suratadenoturev is a gene-modified oncolytic adenovirus expressing the telomerase reverse transcriptase gene.
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 27
- Registration Number
- NCT06340711
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
Phase 2 Study of OBP-301 (Telomelysinâ„¢) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
Phase 2
Terminated
- Conditions
- Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
- Interventions
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 1
- Registration Number
- NCT04685499
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 17
- Registration Number
- NCT03921021
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Syneos Health
- Target Recruit Count
- 4
- Registration Number
- NCT03190824
- Locations
- 🇺🇸
Research Site, Morristown, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath